BioTech, Health Policy, Patient Experience and Survey

In U.S. Health Care, It’s Still the Prices, Stupid – But Transparency and Consumer Behavior Aren’t Working As Planned

Health Populi

JANUARY 18, 2019

As the Harvard Chan-POLITICO study points out, prescription drug costs are top-of-mind for health consumers in America. First, a Wall Street Journal profile of Bluebird Bio , a biotech firm that plans to sell gene-replacement therapy extending annual payments to patients based on whether the drug is effective.

BioTech

BioTech Medicare Medical Billing Patient Experience

A Matter of Trust, Perception, Risk, and Uncertainty – The Big Issues Raised by the Acquisition of PatientsLikeMe and Other Patient Data Transactions

Health Populi

JULY 1, 2019

To address that challenge, in 2017 PLM secured a $100 million (controlling interest) investment from iCarbonX , a Chinese company that is amassing patient data to discover cures for disease. When this occurred, it didn’t cause more than a ripple of interest outside biotech. A 2018 national survey found that 39% of U.S.

Pharmaceuticals

Pharmaceuticals HIPAA BioTech Patient Experience

Most Americans Across Party ID Favor U.S. Government Negotiation to Lower Rx Drug Costs

Health Populi

MARCH 6, 2019

KFF surveyed 1,440 adults 18 and over by phone between February 14th–24th 2019. Health Populi’s Hot Points: This week, Eli Lilly announced that they would introduce a generic form of Humalog , the company’s insulin product, at a price 50% lower than the brand.

Pharmaceuticals

Pharmaceuticals Life Science Medicare BioTech

Connected Health Pulse

In U.S. Health Care, It’s Still the Prices, Stupid – But Transparency and Consumer Behavior Aren’t Working As Planned

A Matter of Trust, Perception, Risk, and Uncertainty – The Big Issues Raised by the Acquisition of PatientsLikeMe and Other Patient Data Transactions

Most Americans Across Party ID Favor U.S. Government Negotiation to Lower Rx Drug Costs

Stay Connected